ZBP1 promotes LPS-induced cell death and IL-1β release via RHIM-mediated interactions with RIPK1

Hayley I. Muendlein, Wilson M. Connolly, Zoie Magri, Irina Smirnova, Vladimir Ilyukha, Avishekh Gautam, Alexei Degterev & Alexander Poltorak

Inflammation and cell death are closely linked arms of the host immune response to infection, which when carefully balanced ensure host survival. One example of this balance is the tightly regulated transition from TNFR1-associated pro-inflammatory complex I to pro-death complex II. By contrast, here we show that a TRIF-dependent complex containing FADD, RIPK1 and caspase-8 (that we have termed the TRIFosome) mediates cell death in response to Yersinia pseudotuberculosis and LPS. Furthermore, we show that constitutive binding between ZBP1 and RIPK1 is essential for the initiation of TRIFosome interactions, caspase-8-mediated cell death and inflammasome activation, thus positioning ZBP1 as an effector of cell death in the context of bacterial blockade of pro-inflammatory signaling. Additionally, our findings offer an alternative to the TNFR1-dependent model of complex II assembly, by demonstrating pro-death complex formation reliant on TRIF signaling.
I nnate immune cells rely on NF-κB and mitogen-activated protein kinase (MAPK) signaling cascades downstream of Toll-like receptors (TLRs) to protect the host against pathogens\(^1\). In response, successful pathogens employ mechanisms to circumvent these host inflammatory responses. For example, *Yersinia* bacteria release effector proteins known as *Yersinia* outer proteins (Yops), which are capable of modulating these host responses in favor of bacterial survival and replication\(^2\). One such effector, YopJ blocks activation of the level 3 MAP kinase TAK1 (TGFβ-activated kinase), attenuating host inflammatory and pro-survival signaling\(^3,4\). In response to this blockade, host cells initiate rapid cell death that is crucial for successful bacterial clearance and host survival\(^5,6\). This positions cell death as an important host mechanism to counteract the inhibition of critical inflammatory signaling by pathogens.

Pyroptosis is an inflammatory form of cell death that occurs in response to pathogenic infection and is typically driven by caspase-1 (CASP1) and/or caspase-11 (CASP11)-mediated cleavage of gasdermin D (GSDMD), which drives death by generating IL-1β and IL-18 cytokines. Since it has recently been shown that GSDMD is capable of driving mitochondrial permeabilization, amplifying apoptotic and pyroptotic cell death\(^3\), we were interested to see if GSDMD was required for CASP9 cleavage in our system. However, while CASP9 cleavage was dependent on CASP8, it occurred independently of GSDMD (Supplementary Fig. 1a,b). It is important to note that while deficiency in GSDMD did not affect caspase cleavage, membrane pore formation and cell death, as measured by release of intracellular contents were abrogated in the absence of GSDMD (Supplementary Fig. 1b).

Reinforcing the importance of TRIF in initiating CASP8-mediated cell death pathways in response to LPS/5z7, LPS and TAK1-mediated phosphorylation of RIPK1 at S321 was attenuated in the absence of TRIF (Fig. 1d). In addition, phosphorylation of RIPK1 at S166, a hallmark of RIPK1 activation, as well as degradation of total RIPK1 were TRIF-dependent (Fig. 1d). To gain further insight into the mechanism of TRIF-driven pyroptosis, we compared the genes that were upregulated in response to LPS/5z7 in B6, *Myd88*\(^−/−\), and *Trif*\(^−/−\) BMDMs (Fig. 1e). Of the 246 genes that were upregulated in susceptible (B6 and *Myd88*\(^−/−\)), but not protected *Trif*\(^−/−\) BMDMs, many were involved in Type I interferon responses (Fig. 1e, f, Supplementary Fig. 2a). This indicated that IFN induction downstream of TRIF might be responsible for regulating specific interferon-stimulated genes (ISGs) that drive CASP8-mediated cell death. Indeed, compared to B6, *Ifnb*\(^−/−\), and *Ifnar*\(^−/−\) BMDMs exhibited decreased cell death, which could be enhanced by reconstitution with recombinant IFNβ prior to LPS/5z7 treatment in *Ifnb*\(^−/−\) macrophages (Supplementary Fig. 2b). Furthermore, inhibition of IFN signaling in B6 BMDMs using IFNAR blocking antibody was sufficient to recapitulate the decrease in death observed in *Ifnb*\(^−/−\) and *Ifnar*\(^−/−\) BMDMs (Supplementary Fig. 2b).

**Results**

**TRIF is required for CASP8-mediated cell death.** To aid in a thorough mechanistic inquiry of CASP8-mediated cell death, we used bone marrow-derived macrophages (BMDMs) activated with lipopolysaccharide (LPS) and the small-molecule inhibitor of TAK1, SZ-7-Oxazaoenol (5z7) to mimic *Yersinia* infection\(^1,11,12\). As we have shown previously\(^11\), LPS/5z7 induced a mixed cell death phenotype, that was partially dependent on the kinase activity of RIPK1, the apoptotic cascades CASP3 and CASP7, and the effector of pyroptosis GSDMD, and entirely dependent on CASP8 (Fig. 1a). Using this model, we identified the TLR4 adaptor TRIF as an important mediator of CASP8-driven cell death, as death in *Trif*\(^−/−\) BMDMs treated with LPS/5z7 was abrogated to levels similar to those induced by 5z7 alone, which induces a mechanistically divergent, TRIF-dependent form of necrotic cell death that is also dependent on CASP8 as described previously\(^11\) (Fig. 1b). However, cell death occurred independently of the other main TLR4 adaptor MyD88 (Fig. 1b).

Although LPS/5z7 treatment induced rapid and abundant cleavage of caspase-8, 3, 7, 9, and GSDMD downstream of CASP8 in wild-type (B6) BMDMs, activation of these caspases was delayed and attenuated in the absence of TRIF (Fig. 1c). Cleavage of CASP9 is often indicative of mitochondrial or intrinsic apoptosis. Since it has recently been shown that GSDMD is capable of driving mitochondrial permeabilization, amplifying apoptotic and pyroptotic cell death\(^3\), we were interested to see if GSDMD was required for CASP9 cleavage in our system. However, while CASP9 cleavage was dependent on CASP8, it occurred independently of GSDMD (Supplementary Fig. 1a,b). It is important to note that while deficiency in GSDMD did not affect caspase cleavage, membrane pore formation and cell death, as measured by release of intracellular contents were abrogated in the absence of GSDMD (Supplementary Fig. 1b).

...
our hypothesis that ZBP1 may play a role in the regulation of CASP8-mediated cell death, Zbp1−/− BMDMs exhibited attenuated death as measured by propidium iodide (PI) incorporation and lactate dehydrogenase (LDH) release in response to LPS/5z7, similar to what we observed in the absence of TRIF and the kinase activity of RIPK1 (Fig. 2b, c). Importantly, while ZBP1 deficiency attenuated cell death in response to LPS/5z7, Zbp1−/− BMDMs recapitulated B6 in response to 5z7 treatment alone, indicating that the role for ZBP1 was specific to LPS/5z7-induced cell death (Supplementary Fig. 2f). However, cell death was not completely abrogated in the absence of ZBP1, and like B6, the remaining cell death in Zbp1−/− relied on CASP8 and RIPK1.
kinase activity, as treatment with the caspase inhibitor zVAD and/or the RIPK1 kinase inhibitor Nec-1 decreased death (Fig. 2d). This suggested that ZBP1 deficiency alters the kinetics and extent, but not the mode of cell death. While death was delayed in the absence of ZBP1, TRIF deficiency provided stronger protection, supporting a role for ZBP1 downstream of TRIF-mediated signaling (Fig. 2b). In confirmation of the mechanism of cell death occurring in Zbp1−/− BMDMs, LPS/5z7 treatment resulted in cleavage of CASP8, 3, 7, 9, and GSDMD (Fig. 2e), indicating that ZBP1 is involved in the regulation of both apoptotic and pyroptotic cell death pathways in response to LPS/5z7. While this was in stark contrast to the complete abrogation of caspase and GSDMD activation observed in Trif−/−, the kinetics of these cleavage events were delayed by ZBP1 deficiency (Figs. 1c, 2e). Furthermore, TAK1 and MAPK-mediated phosphorylation of RIPK1 at S321, and LPS/5z7-mediated
phosphorylation of RIPK1 at S166 were attenuated in Zbp1−/− BMDMs, though to a lesser extent than in the absence of TRIF (Fig. 2f). These data suggest that ZBP1 may regulate recruitment of RIPK1 into a complex (such as TNFR1-associated complex 1) in which both pro-survival and pro-death modifications of RIPK1 occur. Taken together, these results indicate that although ZBP1 is not absolutely required for CASP8-mediated cell death, the efficiency of this pathway is dependent on ZBP1.

Based on the attenuation of CASP8-mediated GSDMD cleavage in Zbp1−/− BMDMs, we were interested to see if ZBP1 was required for inflammasome activation and IL-1β release. We have recently shown that priming with LPS prior to 5z7 treatment upregulated pro-IL-1β and NLRP3 inflammasome components, allowing for CASP8-dependent mature IL-1β release, while simultaneously delaying the onset of cell death due to upregulation of pro-survival factors such as cFLIP (cellular FLICE-like inhibitory protein)22. Accordingly, we pre-primed B6 and Zbp1−/− BMDMs with LPS for 4 h prior to the addition of LPS/5z7, and observed upregulation and cleavage of pro-IL-1β that was dependent on ZBP1 (Fig. 2g). Furthermore, LPS/5z7 treatment induced cleavage of inflammatory CASP1, which was delayed in Zbp1−/−, and by LPS priming (Fig. 2g). Indeed, ZBP1 deficiency decreased IL-1β release and inflammasome activation, as measured by the percentage of ASC speck-positive cells after treatment with LPS/5z7 in LPS-preprimed macrophages (Fig. 2h, i). These data supported previous reports that ZBP1 regulates NLRP3 inflammasome activation and IL-1β release in response to influenza A viral infection20. Decreased upregulation of inflammasome components (CASP1 and pro-IL-1β), as well as decreased RIPK1 S321 phosphorylation (Fig. 2i) in response to LPS in Zbp1−/− suggests that ZBP1 may be involved in TRIF-mediated signaling in response to LPS (Fig. 2g). Indeed, ZBP1 deficiency decreased TRIF, TNF, and IFNβ mRNA levels in response to LPS and LPS/5z7, indicating that ZBP1 may regulate inflammasome signaling at multiple levels (Supplementary Fig. 3a).

To confirm that TRIF and ZBP1 are functioning within the same pathway to drive CASP8-mediated cell death, we knocked down (KD) ZBP1 in Trif−/− and RIPK1 kinase-inactive BMDMs (Supplementary Fig. 3b). While ZBP1 KD inhibited death in B6 BMDMs, deficiency in ZBP1 provided no further attenuation of death on the Trif−/− and RIPK1 kinase-inactive background, indicating that ZBP1 functions within the TRIF-mediated pathway to regulate RIPK1 binding interactions or localization (Supplementary Fig. 3c). In further confirmation of the importance of ZBP1 in TRIF-mediated pro-death signaling, both TRIF and ZBP1 deficiency decreased death in response to the TLR3/TRIF ligand Poly I:C in the context of TAK1 inhibition with 5z7 (Supplementary Fig. 3d).

**ZBP1 promotes cell death via constitutive binding to RIPK1.** To better understand the mechanism of regulation of CASP8-mediated cell death by ZBP1, we immunoprecipitated ZBP1 in resting, LPS- or LPS/5z7-treated BMDMs and probed for binding interactions with RIPK1 and CASP8 (Fig. 3a, Supplementary Fig. 4a). Surprisingly, we observed interaction of ZBP1 and RIPK1 in untreated and LPS-treated cells, which was decreased after 2 h of LPS/5z7 treatment, accompanied by the appearance of ZBP1-bound active CASP8 (Fig. 3a, Supplementary Fig. 4a), indicative of complex II assembly. Although constitutive binding of ZBP1 and RIPK1 has not been previously reported, this may elucidate findings that ZBP1-mediated necroptosis drives perinatal lethality in RIPK1R1HM/R1HM mutant mice23,24. These reports demonstrate that RIPK1, through RHIM-mediated interactions serves as a brake to prevent ZBP1–RIPK3 binding and necroptosis. Constitutive binding between ZBP1 and RIPK1, and the appearance of active CASP8 bound to ZBP1 after LPS/5z7 treatment supported the hypothesis that ZBP1 may regulate CASP8-mediated cell death via RHIM interactions with RIPK1. To confirm this, we generated FLAG-tagged mutant ZBP1 constructs lacking one or both RHIM domains (Fig. 3b). Reconstitution of Zbp1−/− BMDMs with full-length ZBP1 (FL ZBP1), or ZBP1 lacking RHM2 (ZBP1-R2) nearly recapitated the extent of cell death observed in B6 BMDMs (Fig. 3b, d). However, reconstitution with ZBP1 constructs lacking RHM1 (ZBP1-R1) and ZBP1-R1/2 failed to increase death in Zbp1−/− BMDMs, indicating a role for RHM1 in LPS/5z7-induced death (Fig. 3b, d). ZBP1 is also composed of Z-DNA binding domains capable of sensing DNA and RNA viruses, and driving cell death25. Thus, we generated FLAG-tagged mutant constructs of ZBP1 lacking one or both Z-DNA binding domains and tested their capacity to rescue death in response to LPS/5z7 in Zbp1−/− BMDMs (Fig. 3c, e). All mutant constructs recapitated reconstitution with full-length ZBP1, indicating that the Z-DNA-binding domains of ZBP1 are not required for CASP8-mediated cell death. To determine if ZBP1-R1 failed to elicit cell death due to loss of binding interactions with RIPK1 or CASP8, we precipitated exogenous ZBP1 RHM mutant proteins with FLAG antibodies in Zbp1−/− BMDMs (Fig. 3f, Supplementary Fig. 4b, c). Strikingly, deficiency in RHM1 prevented ZBP1–RIPK3 binding as well as downstream CASP8 binding and activation (Fig. 3f, Supplementary Fig. 4b, c). This data was in agreement with earlier overexpression-based studies in 293T and L929 cell lines showing a requirement for RHM1-mediated ZBP1–RIPK1 binding in the regulation of NF-κB activation26,27. Altogether, these findings suggest that ZBP1 promotes cell death in BMDMs by functioning as a scaffold protein rather than a sensor of nucleic acids.

**TRIF induces complex formation independently of TNFR1.** Recently, we have shown that LPS/5z7 treatment induced the formation of a complex II-like protein complex containing FADD, RIPK1, CASP8 by decreasing cellular stores of the CASP8 homolog cFLIP. Furthermore, successful initiation of this complex was required for CASP8 activation and subsequent pyroptosis22. Complex II formation has been most extensively studied downstream of TNF receptor 1 (TNFR1)28. However, lack
of TNFR1 had no effect on CASP8-mediated cell death induced by LPS/5z7 treatment as measured by PI incorporation and further confirmed by LDH release (Fig. 4a, b). Instead, LPS/5z7-induced death was highly dependent on TRIF, TRIF-associated adaptor (TRAM)29, and the LPS-co-receptor CD14 (Fig. 4a) responsible for LPS-induced endocytosis of TLR430. To further investigate the role of TNFR1 signaling in LPS/5z7-induced cell death, we treated B6, Trif−/−, Tnfr−/−, and Zbp1−/− BMDMs with LPS/5z7 in the presence of TNF-neutralizing antibodies (aTNF) (Fig. 4c). While aTNF had no effect in B6 and Tnfr−/−, aTNF treatment resulted in a modest, yet statistically significant decrease in death in Trif−/− and Zbp1−/− BMDMs, indicating that TNFR1 signaling may contribute to cell death in the absence of sufficient TRIF-mediated signaling (Fig. 4c). However, the physiological significance of this modest decrease in cell death remains to be further explored. In confirmation of the efficacy of the TNF-neutralizing antibody in inhibition of TNF signaling, treatment with aTNF abrogated 5z7-induced cell death, which we have previously shown to be TNF-dependent11 (Fig. 4d).

In the context of TLR4 signaling, CD14 serves dual functions as (1) an LPS-co-receptor important for TLR4-mediated responses to LPS and (2) a cell surface protein that regulates endocytosis of TLR4 to promote TRIF-mediated responses30,31. In order to decouple the requirement for these two functions in the context of LPS/5z7-induced cell death, we treated B6 and Cd14−/− BMDMs with the endocytosis inhibitor Dynasore (Fig. 4e). Treatment of B6 BMDMs with Dynasore recapitulated the phenotype of Cd14−/− BMDMs, suggesting that endocytosis is required for LPS/5z7-induced cell death (Fig. 4e).

Lack of TRIF-specific antibodies complicated our ability to specifically observe TRIF localized within the complex. However, we were able to assess the relative contribution of TRIF and TNFR1 to complex formation using Trif−/− and Tnfr−/− BMDMs (Fig. 4f–h). TNFR1 had no impact on complex formation, as RIPK1 and CASP8 bound to FADD comparably to B6 in Tnfr−/− (Fig. 4h). In contrast, TRIF was absolutely required for complex formation, and CASP8 was not activated under the same conditions in Trif−/− BMDMs (Fig. 4g). To reflect the fact that TRIF, and not TNFR1 signaling was responsible for complex formation and activation of CASP8-mediated cell death, we termed this complex the TRIFosome32.

In addition to the role of TRIF in TRIFosome formation and cell death, TRIF but not TNFR1 was required for LPS/5z7-induced IL-1β release (Fig. 4i). The abrogation of IL-1β release in Trif−/− BMDMs was even greater than in the absence of ZBP1, supporting the role for ZBP1 downstream of TRIF. LPS/5z7-induced IL-1β release was dependent on the NLRP3 inflammasome, as deficiency in NLRP3 or treatment with the NLRP3 inhibitor MCC950 largely attenuated IL-1β release (Fig. 4i).
ZBP1 and RIPK1 kinase activity regulate TRIFosome formation. Interestingly, binding of ZBP1 to the TRIFosome indicated that ZBP1 might regulate the extent of CASP8-mediated cell death by controlling complex formation (Fig. 4g, h). To begin to address this question, we performed a time course of ZBP1-specific immunoprecipitations, and probed for critical TRIFosome components RIPK1 and CASP8 (Fig. 5a). As before, ZBP1 and RIPK1 were constitutively bound, with loss of ZBP1–RIPK1 interactions occurring at later time points after LPS/Sz7 treatment (Fig. 5a), likely due to degradation of RIPK1 by CASP8 in complex, as both RIPK1 loss, and the presence of cleaved CASP8 were inhibited by treatment with zVAD and Nec-1 (Fig. 5a). This is in agreement with decreases in total RIPK1 levels that we have seen in response to LPS/Sz7 treatment (Figs. 1d, 2f). In addition, we observed RIPK1...
Fig. 4 TRIF induces complex formation independently of TNFR1. a, b Cell death over time in indicated BMDMs stimulated with LPS/5z7 as measured by a propidium iodide (PI) incorporation or b LDH release. c–e Cell death over time as measured by PI incorporation in indicated BMDMs treated with c LPS/5z7+/− TNF-neutralizing antibody, d 5z7+/− TNF-neutralizing antibody or e Dynasore endocytosis inhibitor. f–h FADD immunoprecipitation in f B6, g TRif+/−, and h TRif−/− BMDMs stimulated as indicated and probed for ZBP1, RIPK1, and CASP8. 1 IL-1β release after 6 h in indicated BMDMs treated with LPS; LPS pre-primed LPS/5z7, or LPS pre-primed LPS/5z7 in the presence of NLPR3 inflammasome inhibitor MCC950. Data from cell death assays and western blots are representative of 3 or more biologically independent experiments, cell death data are presented as the mean ± SD of triplicate wells, n = 10,000 cells examined in three individual wells. IL-1β release data are presented as the mean ± SD for triplicate wells from n = 4 biologically independent experiments. Two-way analysis of variance (ANOVA) was used for comparison between groups. Source data for all experiments are provided as a Source data file.

phosphorylated at S321 and S166 bound to ZBP1, suggesting that these modifications occur within the complex, and supporting our hypothesis that ZBP1-mediated recruitment of RIPK1 regulates RIPK1 post-translational modifications within the TRIFosome (Fig. 5a). However, while we were able to detect ZBP1 bound in FADD immunoprecipitations (Fig. 4f, g), we were unable to detect FADD bound to ZBP1, indicating that ZBP1 interactions with the TRIFosome were highly transient. To address this, we performed FADD immunoprecipitations to assess the requirements for ZBP1 interactions with TRIFosome components. Indeed, ZBP1, as well as RIPK1 and CASP8 co-precipitated with FADD as early as 1 h after treatment of B6 BMDMs with LPS/5z7 (Fig. 5b). However, treatment with LPS/5z7 at later time points abrogated ZBP1:FADD binding, thus confirming a crucial role of ZBP1 specifically in the initiation of complex formation (Fig. 5b). Interestingly, stimulation of BMDMs with LPS alone preserved binding of ZBP1 to FADD, supporting further investigation of this complex in the context of a strictly pro-inflammatory response. Furthermore, this LPS-induced ZBP1:FADD binding was preserved and enhanced in RIPK1 kinase-inactive BMDMs (Fig. 5b). Conversely, binding of all TRIFosome components in response to LPS/5z7 was abrogated in RIPK1 kinase-inactive BMDMs (Fig. 5b), indicating that kinase activity of RIPK1 was required for pro-death TRIFosome formation. RIPK1 kinase activity was not important for constitutive ZBP1–RIPK1 binding, indicating that RIPK1 kinase activity is required for TRIFosome formation downstream of ZBP1 (Fig. 5c). While caspase inhibition had no effect on RIPK1 binding to ZBP1 (Fig. 5a), CASP8 deficiency decreased RIPK1 and ZBP1 binding to FADD at all time points, demonstrating that the presence of CASP8 likely stabilizes, but is not strictly required for complex formation (Fig. 5d). Finally, ZBP1 deficiency delayed TRIFosome formation and decreased the efficiency of RIPK1 binding and downstream CASP8 activation (Fig. 5e).

The TRIFosome regulates cell death in response to Yersinia. Recent reports have demonstrated a role for TNF signaling in driving CASP8 and RIPK1-mediated cell death in vitro, and promoting mouse survival in vivo in response to Y. pseudotuberculosis (ΔHop1) Y. pseudotuberculosis. Y. pseudotuberculosis infection of wild-type macrophages at both high (MOI 30) and low (MOI 7.5) concentrations induced cell death that was dependent on YopI, the Yersinia effector protein capable of blocking TAK1 activation, as ΔHop1 Yersinia failed to induce death comparable to wild-type (WT) infection (Fig. 6a). However, Yersinia-induced cell death occurred more quickly at higher MOI (Fig. 6a). Similar to treatment with LPS/5z7, infection of macrophages at high MOI induced cell death that was dependent on TRIF, ZBP1, and the kinase activity of RIPK1, and independent of TNFR1 (Fig. 6b). However, unlike treatment with LPS/5z7 or high MOI Yersinia infection, which likely provide complete inhibition of TAK1 signaling, infection of macrophages at low MOI induced cell death that was additionally dependent on TNFR1, suggesting that in the absence of complete inhibition of pro-inflammatory signaling, TNF signaling amplifies cell death in response to Yersinia infection (Fig. 6c). In further support of the importance of the TRIFosome in Yersinia infection, cleavage of CASP8 was inhibited nearly entirely in the absence of TRIF, and partially in the absence of ZBP1 and RIPK1 kinase activity in the context of high MOI Yersinia infection (Fig. 6d).

In agreement with incomplete inhibition of pro-inflammatory signaling in response to low MOI Yersinia infection, infection of macrophages at 7.5 MOI induced IL-1β release that was dependent on TRIF, TNFR1, ZBP1, and RIPK1 kinase activity (Fig. 6e). However, at 30 MOI, Yersinia infection failed to induce IL-1β release, likely due to complete inhibition of pro-IL-1β synthesis at higher MOI (Fig. 6e). In support of this, priming of macrophages with LPS prior to high MOI Yersinia infection rescued IL-1β release. Similar to cell death, IL-1β release in response to high MOI Yersinia infection was independent of TNFR1 (Fig. 6e). Taken together, these results suggest that TRIFosome components are highly necessary for cell death and IL-1β release in response to Yersinia infection, and that TNFR-signaling amplifies these processes when pro-inflammatory signaling is not completely inhibited (low MOI infection), and onset of death is delayed.

Discussion

These results support a model in which, upon LPS induction in the context of TAK1 inhibition via 5z7 or Yersinia infection, CD14-dependent translocation of TLR4 to the endosome permits TRIF binding to ZBP1, possibly via RHIM domain interactions. This binding recruits RIPK1, due to its engagement in constitutive RHIM:RHIM interactions with ZBP1, followed by recruitment of FADD and CASP8 downstream of TRIF (Fig. 6f). This model is in agreement with the importance of TRIF and ZBP1 for S166 phosphorylation of RIPK1, promoting the kinase function of RIPK1 required for complex formation with FADD and CASP8. Furthermore, ZBP1-dependent recruitment of RIPK1 and CASP8 to the TRIFosome is required for inflammasome activation and IL-1β release.

Despite the lack of TRIF-specific antibodies, as well as the robust cytotoxicity induced by exogenous TRIF expression, the striking dependence on TRIF, and relative independence from TNFR1 signaling, supported defining this ZBP1–RIPK1–FADD–CASP8-containing complex as the TRIFosome. Interestingly, in the context of insufficient TRIF signaling, or when pro-inflammatory signaling is only partially inhibited, as is the case with low MOI Yersinia infection, signaling through TNFR1 seems to supplement TRIF-mediated cell death and IL-1β release. In this regard, it would be interesting to assess the importance of TRIFosome formation in the context of the recently characterized CASP8–mediated cell death that occurs in response to TNF and TAK1 inhibition. Although RHIM-mediated interactions between ZBP1 and RIPK1 have likely been assumed by many in the field, until now, the evidence for these interactions was largely based on overexpression studies in 293T and L929 cell lines, and had not been shown in primary cells. In addition, these RHIM-mediated interactions between RIPK1 and ZBP1 were mainly shown to regulate...
Fig. 5 ZBP1 and RIPK1 kinase activity regulate TRIFosome formation. a ZBP1 immunoprecipitation in B6 BMDMs stimulated as indicated and probed for RIPK1 and CASP8. b FADD and c ZBP1 immunoprecipitations in B6 and RIPK1 kinase-inactive BMDMs stimulated as indicated and probed for ZBP1, RIPK1, and CASP8. d, e FADD immunoprecipitation in B6, d Ripk3<sup>−/−</sup>/Casp8<sup>−/−</sup> or e Zbp1<sup>−/−</sup> BMDMs stimulated as indicated and probed for ZBP1, RIPK1, and CASP8. Data from western blots are representative of 3 or more biologically independent experiments. Source data for all experiments are provided as a Source data file.
pro-inflammatory NF-κB activation, while recent studies of the pro-death role of ZBP1 have focused extensively on ZBP1–RIPK3-mediated necroptosis in response to viral infection, which is dependent on ZBP1 Z-DNA binding domains\(^{17,20,25,37}\). Therefore, we have identified a novel mechanism through which ZBP1–RIPK1 RHIM-mediated interactions drive not only pro-inflammatory signaling, but also rapid CASP8-mediated cell death in response to bacterial infection. How ZBP1 promotes CASP8-mediated cell death has yet to be fully characterized, but its contribution to complex formation appears to facilitate interactions between the RHIM domain-containing proteins RIPK1 and TRIF, thereby initiating activation of CASP8. Due to the fact that binding of ZBP1 to FADD seems to be highly transient relative to other TRIFosome interactions, with ZBP1 only detectable at very early time points after LPS/5z7 treatment, it is tempting

---

**Fig. 6 The TRIFosome regulates cell death in response to Yersinia.** a Cell death as measured by propidium iodide (PI) incorporation in B6 BMDMs infected with wild-type or YopJ-deficient (ΔYopJ) Y. pseudotuberculosis at indicated MOI. b, c Cell death as measured by PI incorporation in indicated BMDMs infected with wild-type Y. pseudotuberculosis at b 30 MOI or c 7.5 MOI. d CASP8 cleavage in indicated BMDMs infected with wild-type Y. pseudotuberculosis at 30 MOI for 2 h. e IL-1β release after 6 h of wild-type Y. pseudotuberculosis infection at 7.5 or 30 MOI in indicated BMDMs that were primed or unprimed with LPS for 4 h prior to infection. f Model of ZBP1-regulated TRIFosome formation leading to CASP8-mediated pyroptosis and IL-1β release. Data from cell death assays and western blots are representative of 3 or more biologically independent experiments, cell death data are presented as the mean ± SD of triplicate wells, \(n = 10,000\) cells examined in three individual wells. IL-1β release data are presented as the mean ± SD for triplicate wells from \(n = 3\) biologically independent experiments. Two-way analysis of variance (ANOVA) was used for comparison between groups. Source data for all experiments are provided as a Source data file.
to postulate that ZBP1 may serve a shuttle function, initiating complex formation by providing cellular stores of RIPK1 to TRIF- and IRF3-mediated pathways which in both cases are responsible for the regulatory role of ZBP1 in the context of influenza A infection. Our findings, pointing toward a TRIF-ZBP1-CASP8-mediated axis of regulation for cell death and inflammation signaling are in agreement with in vivo responses in these two infection models, which in both cases are critical for host survival. Therefore, identification of ZBP1-regulated TRIFosome formation, CASP8 activation, and IL-1β production provides novel points of regulation that could be relevant in the context of various pathogenic infections.

Methods

Mice and macrophages. C57BL/6 (B6), Ticam−/−, C57BL/6-Ticam11 (REF), Cldn−/−, (B6.129S2-Cldn8−/−, Jax), MyD88−/−, (B6.129S2-Myd88tm1.1Defr), Trif−/−, (C57BL/6-Traf3fl/flΔPAC), and Nramp−/− (B6.129S6- Nramp1tm1(Morl)) mice were obtained from The Jackson Laboratory. Ibyn−/− (C57BL/6 background) were a gift from Dr. S. Vogel. Mice were housed according to protocols approved by the Tufts University Medical School Animal Care and Use Committees. Mice were housed in ambient temperature and humidity in ventilated cages systems on a 12 h light cycle. All mice used were in a single pathogen-free facility. No more than 4 mice were housed in a single cage. Femurs from Ticam2fl/−/− (Tram−/−, C57BL/6 background) mice were generously donated by Dr. L. Li. Femurs from Ripk3−/− (C57BL/6 background) and Gsdmd−/− (C57BL/6 background) mice were donated by Dr. K. Fitzgerald, and were generated by Dr. V. Dist. Ripk311 (RIPK1 KI, C57BL/6 background) mice were provided by Dr. A. Degtereve. Femurs from Ripk3−/−/Casp8−/− (C57BL/6 background) mice were donated by Dr. K. Fitzgerald, and were originally generated by Dr. D. Green. Femurs from Zbp1−/− (C57BL/6 background) mice were generously donated by Dr. S. Balachandran. Bones from Casp3−/− (Casp3−/−, C57BL/6 background) were generated and provided by Dr. A. Rongvaux. Bone marrow was isolated from the long bones of 6–12 week-old male and female mice, propagated in RPMI containing 20% FBS, 2% Pen-Strep, and 30% L cell supernatant on non-tissue culture-treated Petri dishes. Once differentiated, BMDMs were plated for experiments at a density of 1 × 10^6 cm^-2 in RPMI containing 20% FBS and 2% Pen-Strep. Immortalized Ripk3−/−/Casp8−/−, Zbp1−/−, and B6 BMDMs were generated and donated by Dr. K. Fitzgerald.

Reagents. Lipopolysaccharide (LPS) Escherichia coli 011:B4 (10 ng/ml, L4391), 5Z-2′-Oxo-Hx401 (5C7, 125 μg/ml), MyD88 (B6.129S2-Myd88tm1.1Defr), Traf3fl/flΔPAC (C57BL/6 background), were purchased from Sigma. zVAD.fmk was purchased from Millipore (219007) and control IgG was purchased from BD Pharmingen. Dynasore was purchased from Cell Signaling Technology (11969S) and used at a concentration of 20 μg/ml. Propidium iodide (PI) incorporation was detected at 617 nm, and PI− nuclei were counted. Wells treated with 0.1% Triton X-100 were used as controls for 100% cell death. For Annexin V/PI stained >x20 images in 2G, macrophages were seeded in RPMI buffered at pH 7.2−7.5 (1 mM HEPES) and supplemented with 2 mM CaCl2 to allow for Annexin V binding. Cells were imaged at 30-min intervals at >x2 magnification, PI incorporation was detected at 617 nm, and Annexin V was detected at 350 nm.

LDH cytotoxicity assay. At indicated time points after stimulation with LPS/5z7, cell supernatants were collected and LDH release was measured using CyQuant LDH Cytotoxicity Assay kits (C20300) according to the manufacturer’s instructions. Absorbance at 490 and 689 nm was measured using The Cyation3 automated microscope.

Immunoblotting. After indicated treatments, cells were lysed in 1X Laemmli Buffer containing 5% β-mercaptoethanol, boiled for 15 min and incubated on ice for 15 min. For indicated conditions, proteins were precipitated from cell supernatants by methanol–chloroform extraction, and precipitated proteins were processed as above prior to loading and running on SDS-PAGE gels. Primary antibodies against Casp3 (8592), Casp3 (9665), Casp9 (9508), Casp1 (24232), Casp11 (14340), RIPK3 (14939), pRIPK1 (Ser166) (31122), pRIPK1 (Ser211) (38662), IL-1β (12242), FLAG (8146), and GAPDH (2118) were purchased from Cell Signaling Technologies. ZBP1 antibody (AG-20B-0010-C100) was purchased from Adipogen. GSDMD antibody (ab209845) was purchased from Abcam. FADD antibody (05-486) was purchased from Millipore Sigma. All primary antibodies were used at a dilution of 1:1000. Secondary antibodies, anti-rabbit IgG (H + L) (DyLight780 4X PEG Conjugate) (5151), anti-mouse IgG (H + L) (DyLight780 4X PEG Conjugate) (5277), and HRP-linked anti-rat IgG antibody (7077) were purchased from Cell Signaling Technologies. Fluorescent secondary antibodies were used at a dilution of 1:30,000 and HRP-based secondary antibodies were used at a dilution of 1:2000. Uncropped western blots are available in the Source data file.

Next-generation RNA sequencing. Total RNA was isolated from unstimulated and LPS/5z7 stimulated (1 h) B6, Trif−/− and Mydd88−/− BMDMs using Trizol. A TruSeq kit was used to make a directional cDNA library. Seventy-five bp reads from cDNA libraries were generated on MiSeq (Illumina) and aligned using TopHat2 and Cufflinks software. Long-transformed values of genes that were upregulated after LPS/5z7 stimulation over unstimulated (>1.7-fold) were compared among B6, Trif−/− and Mydd88−/−, and displayed using a Venn Diagram. Genes upregulated in B6 and Mydd88−/− but not Trif−/− were clustered by GeneOntology (GO).

RNA preparation and analysis. Total RNA was isolated from 5 × 10^5 cells after indicated treatments using Trizol, following the manufacturer’s instructions. cDNA was synthesized by reverse transcription, performed using MultiV reverse transcriptase, RNase inhibitor, random primers, and dNTP mix (New England Biolabs). cDNA was analyzed for relative mRNA levels using SYBR Green (Applied Biosystems), and gene-specific primers (Table S1). Actb was used to normalize mRNA levels, and post amplification melting curve analysis was performed to confirm primer specificity.

ELISA. Six hours after indicated treatments, cell supernatants were collected and cytokine secretion was measured by ELISA. Murine IL-1p DuoSet ELISA Kits (DY401) were used according to the manufacturer’s instructions.

ASC speck quantification and high magnification imaging. To quantify ASC+ cells, macrophages were seeded at a density of 1 × 10^6 cm^-2 in RPMI on 1.17-mm-thick glass-bottom imaging plates. As indicated, macrophages were unstimulated or pre-primed with LPS for 4 h prior to treatment with LPS or LPS/5z7 for 2 h. Cells were fixed in 4% paraformaldehyde for 15 min, blocked in 1x PBS (5% FBS, 0.3% Triton X-100), and incubated overnight with anti-ASC antibody (Cell Signaling Technologies, 67824), followed by a 2-h incubation in the presence of Alexa Fluor 488-conjugated-Goat-anti-Rabbit IgG (Invitrogen A-11034), and Hoechst 33342 fluorescent stain. To quantify the percentage of ASC+ cells, the Cytation3 automated microscope was used to image cells at x4 magnification to capture ~5000 cells/field of view in quadruplicate. Hoechst stain was detected at 350 nm and Hoechst+ nuclei were counted to provide total cell count. The ASC signal was detected at 488 nm and ASC specks (1–3 μm) were counted.

Lentivirus constructs and transduction. For ZBP1 reconstitution experiments, full-length and mutated versions of ZBP1 sequences were ligated into a pLEX lentivector. Lentiviral particles were generated by transfection with packaging vector psPAX2 (plasmid 12260; Addgene) and the VSV-G pseudotyping vector pmD2.G (plasmid 12239; Addgene) into the 293FT cell line. Generated lentiviral particles were used to transduce B6, Trif−/−, and Mydd88−/− BMDMs on day 4 of differentiation, followed by puromycin selection (3 μg/ml, 48 h) starting on day 6. Mission shRNA plasmids containing hairpin sequences specific to mouse ZBP1 were identified and purchased from Sigma-Aldrich (5′-CCGGGTCCAGACAGTCCACATCAAAC-3′, CAGGTTTGGFAGGTCATGCTGAACTTFTTG-3′, Scramble control vector CAGTGGGCTGAGAAGGAGTACAACTCTAACAG). Lentiviral particles from shRNA plasmids were generated as described above, and used to transduce indicated BMDMs.
**ZBP1 and FADD Immunoprecipitations.** Indicated BMDMs were plated on 6-well tissue culture-treated plates, stimulated as indicated, and harvested in immunoprecipitation lysis buffer (0.5% Triton X, 20 mM Tris Base (pH 7.4), 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1X protease inhibitor cocktail). Lysed cells were rotated for 60 min at 4°C with intermittent vortexing, centrifuged at 5000 g for 5 min, and the supernatant was incubated with a- FADD, a-ZBP1, or a-FLAG antibody-conjugated Protein G (FADD and ZBP1-specific immunoprecipitations) or Protein A (FLAG-specific immunoprecipitations) agarose beads (Cell Signaling Technology 37478, or 9863). Samples were washed three times in immunoprecipitation lysis buffer, and protein complexes were eluted with 1X Laemmli buffer containing 5% β-mercaptoethanol at 90°C for 15 min.

**Yersinia growth conditions and infection.** Wild-type and ΔYopJ IP2666 Y. pseudotuberculosis bacterial strains were grown plentifully provided by Dr. R. Isberg. Bacteria were grown from frozen glycerol stocks on LB plates containing l-arginase (Sigma). Cultures were grown overnight at 26°C in 2XYT broth, diluted to an OD600 of 0.2, and grown at 26 °C for 2 additional hours prior to a shift to 37 °C for 2 h. Macrophages were infected at MOI 7.5 or 30 CFU/cell as indicated.

**Quantification and statistical analysis.** Error bars in ELISA experiments represent the standard deviation of three independent experiments. Data from kinetic cytotoxicity and ASC+ cell quantification experiments are representative of three or more experiments, and error bars represent the standard deviation between triplicate samples. Immunoblots are representative of three or more independent experiments. Significance was determined using a one-way or two-way ANOVA as appropriate: ns (non-significant) p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability.** Next-generation RNA sequencing data that support the findings of this study have been deposited in the GenBank GEO Database with primary accession code GSE83885. All additional data are available within the paper and its Supplementary Information and Source data files. Reported interferon-stimulated genes within our dataset were identified using the INTERFEROME database (http://www.interferome.org/interferome/site/showCitation.jsp). Source data are provided with this paper.

Received: 4 May 2020; Accepted: 25 November 2020; Published online: 04 January 2021

**References**

1. Neill, L. A. J. O., Golenbock, D. & Bowie, A. G. The history of Toll-like receptors—redefining innate immunity. Nat. Rev. Immunol. 13, 453–460 (2013).

2. Demeure, C. E. et al. Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics. Genes Immun. 20, 357–370 (2019).

3. Mukherjee, S. et al. Yersinia YopJ acetylates and inhibits kinase activation by redox-dependent control of NF-κB activation via the IKKε/NEMO complex. Cell 177, 1794–1808 (2019).

4. Paquette, N. et al. Serine/threonine acetylation of TGFβ receptor type I (TβRI) by Yersinia pestis YopH inhibits innate immune signaling. J. Immunol. 193, 12710–12715 (2014).

5. Weng, D. et al. Caspase-8 and RIP kinases regulate bacteria-induced innate immunity. J. Immunol. 191, 2341–2346 (2013).

6. Liu, X. et al. ZBP1 and FADD Immunoprecipitations. Indicated BMDMs were plated on 6-well tissue culture-treated plates, stimulated as indicated, and harvested in immunoprecipitation lysis buffer (0.5% Triton X, 20 mM Tris Base (pH 7.4), 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1X protease inhibitor cocktail). Lysed cells were rotated for 60 min at 4°C with intermittent vortexing, centrifuged at 5000 g for 5 min, and the supernatant was incubated with a- FADD, a-ZBP1, or a-FLAG antibody-conjugated Protein G (FADD and ZBP1-specific immunoprecipitations) or Protein A (FLAG-specific immunoprecipitations) agarose beads (Cell Signaling Technology 37478, or 9863). Samples were washed three times in immunoprecipitation lysis buffer, and protein complexes were eluted with 1X Laemmli buffer containing 5% β-mercaptoethanol at 90°C for 15 min.

7. He, W. et al. Gasdermin D is an executor of pyroptosis and required for IFNβ induction during Yersinia infection. PLoS Pathog. 16, e1008170 (2020).

8. Malireddi, R. K., Kwon, Y. N., Nagashima, S. & Kanneganti, T. ZBP1 and TAK1: master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis. Front. Cell. Infect. Microbiol. 9, 1–9 (2019).

9. Zhang, T. et al. Influenza virus Z-RNAs induce ZBP1-mediated necroptosis. Cell 178, 1115–1129 (2020).

10. Roy, J. K. et al. ZBP1 and FADD are required to trigger pyroptosis during Yersinia infection. Cell Host Microbe 28, 88–98 (2020).

11. Curci, O. et al. ZBP1mediated pyroptosis requires ZBP1 and TRAF3. J. Exp. Med. 217, 1763–1775 (2020).

12. Park, J. H. et al. ZBP1–FADD-dependent caspase-8 activation promotes innate immune cell death. Cell 179, 990–1002 (2019).

13. Wajant, H. & Siegmund, D. TNFR1 and TNFR2 in the control of the life and death of innate immune cells. Trends Cell Bio. 26, 171–181 (2016).

14. Nogusa, S. et al. RIPK3 activates parallel pathways of MLKL-driven necroptosis and FADD-mediated apoptosis to protect against influenza A virus. Cell Host Microbe 20, 13–24 (2016).

**Acknowledgements**

We thank Dr. K. Fitzgerald and Dr. S. Balachandran for sharing various mouse strains for this study. In addition, we thank Dr. S. Balachandran for reading this manuscript and offering helpful comments and expertise. We thank Dr. R. Isberg for sharing the Y. pseudotuberculosis strains used in this study. We thank A. Tai and the Tufts University Genomics Core for help with RNA sequencing and data analysis. The work was supported by the NIH grants AI056234 to A.P., R21NS111395 and R01AI144400 to A.D.

**Author contributions**

Conceptualization, A.P. and H.M.L.; validation, H.M.L. and W.M.C.; formal analysis, H.M.L. and W.M.C.; investigation, H.L.M., W.M.C., Z.M., I.S., A.G., and V.I.; writing, A.P., H.M.L., W.M.C., and A.D.; visualization, H.M.L. and W.M.C.; supervision, A.P.; A.D.; project administration, A.P.; funding acquisition, A.P.

**Competing interests**

The authors declare no competing interests.
